Grant: Strategic Projects - Group
University of Toronto
$176,000.00
Manufacturing of bioactive molecules using digital microfluidics
FY 2013-14
Summary
This strategic grant application aims to enable manufacturing of a challenging class of molecules. The plan is to build on a collaboration between the labs of Andrei Yudin and Aaron Wheeler at the University of Toronto and to develop a capability to manufacture macrocyclic peptides using digital microfluidics. Macrocycles are larger than the so-called ""small molecules"" which have been the focus of attention in the pharmaceutical industry over the past 20 years. Macrocycles occupy a strategic position that lies in between small molecules and proteins. Due to their higher molecular weight and extended structure, macrocycles are capable of extended interactions with their molecular targets. Our industrial partner is Boehringer-Ingelheim (Laval) who has a long-standing interest in macrocycles. In the course of this collaboration we will develop an automated system that will enable one to take pre-made building blocks and convert them into complex macrocycles using site-specific insertion of molecular fragments. We foresee rapid production of molecules that, due to their complexity, have not been accessible to Boehringer-Ingelheim. We will work together with Dr. Paul Edwards of Boehringer-Ingelheim and will incorporate the input from scientists under his supervision into the molecules we plan to build. Boehringer-Ingelheim will provide us with the pharmacokinetics and proteolytic stability data for our compounds. Our relationship with Boehringer-Ingelheim will enable us to validate the foundational science for Encycle and Kapplex, the two start-up companies that are being started by Yudin and Wheeler in cooperation with MaRS Innovation. These start-ups are going to provide job opportunities to Canadian university graduates. At the moment, students are having extremely difficult time securing employment. We will help build a new high tech manufacturing sector. Our IP position is strong (Yudin: 4 patents in the past year, Wheeler: 5 patents). Last but not least, we will work with Sigma-Aldrich on scale-up and world-wide supply of ""active amide"" scaffolds. Together with Dr. Mark Redlich of Sigma-Aldrich, we already have an extensive experience in bringing reagents to the synthetic community.
Program
Strategic Projects - Group
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
413042-2011
Name nom
Yudin, Andrei
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2011
Award amount
176000
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1570
Committee name en
Strategic Projects Selection Panel - Manufacturing - B
Committee name fr
Comité de sélection des projets stratégiques - Fabrication - B
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
3
Nb partie
3
Application title
Manufacturing of bioactive molecules using digital microfluidics
Keyword
NSERC
Application summary
This strategic grant application aims to enable manufacturing of a challenging class of molecules. The plan is to build on a collaboration between the labs of Andrei Yudin and Aaron Wheeler at the University of Toronto and to develop a capability to manufacture macrocyclic peptides using digital microfluidics. Macrocycles are larger than the so-called ""small molecules"" which have been the focus of attention in the pharmaceutical industry over the past 20 years. Macrocycles occupy a strategic position that lies in between small molecules and proteins. Due to their higher molecular weight and extended structure, macrocycles are capable of extended interactions with their molecular targets. Our industrial partner is Boehringer-Ingelheim (Laval) who has a long-standing interest in macrocycles. In the course of this collaboration we will develop an automated system that will enable one to take pre-made building blocks and convert them into complex macrocycles using site-specific insertion of molecular fragments. We foresee rapid production of molecules that, due to their complexity, have not been accessible to Boehringer-Ingelheim. We will work together with Dr. Paul Edwards of Boehringer-Ingelheim and will incorporate the input from scientists under his supervision into the molecules we plan to build. Boehringer-Ingelheim will provide us with the pharmacokinetics and proteolytic stability data for our compounds. Our relationship with Boehringer-Ingelheim will enable us to validate the foundational science for Encycle and Kapplex, the two start-up companies that are being started by Yudin and Wheeler in cooperation with MaRS Innovation. These start-ups are going to provide job opportunities to Canadian university graduates. At the moment, students are having extremely difficult time securing employment. We will help build a new high tech manufacturing sector. Our IP position is strong (Yudin: 4 patents in the past year, Wheeler: 5 patents). Last but not least, we will work with Sigma-Aldrich on scale-up and world-wide supply of ""active amide"" scaffolds. Together with Dr. Mark Redlich of Sigma-Aldrich, we already have an extensive experience in bringing reagents to the synthetic community.